Exchange: NASDAQ·Updated 07:30 PM EDT

ALKS News

News
all
press releases
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the companys third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes...
Business Wire
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the companys third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes...
Business Wire
More News
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
Harmony Biosciences gains 27.6% in six months as Wakix sales surge and pipeline advances, with new formulations and clinical milestones offering further growth opportunities.
Zacks
Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
Alkermes plc (Nasdaq: ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Societys (ESRS) 28th Congress, Sleep Europe 2026, taking place Oct. 20-23, 2026 in Maastricht, the...
Business Wire
4 CNS Drug Stocks Worth Watching This World Mental Health Day
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
Zacks
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.
Zacks
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
Zacks
Meta To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts upgraded Fifth Third to Buy and adjusted price targets for Exelon, Alaska Air, Fair Isaac, Meta, Alkermes, Twilio and Warner Bros. Discovery.read more...
Benzinga
Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment
Alkermes reports positive Phase 1b data for ALKS 7290, showing clinical proof-of-concept for ADHD treatment. Learn key findings.read more...
Benzinga
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the companys novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD). The study...
Business Wire

Advertisement|Remove ads.